Introduction
The role of microRNAs is being increasingly recognized in a number of diverse cellular processes, including oncogenesis 1,2 and immune cell function 3, 4 . Efforts towards a comprehensive characterization of microRNA-expression in cellular systems are limited by the continuing discovery of new microRNAs. Over a hundred new microRNAs have been identified in humans in the past two years 5 . Thus, microRNA platforms used to measure microRNA expression in any biological system are frequently obsolete by the time the studies are published.
Bioinformatic analyses of the genome suggest that there might be thousands of microRNAs encoded in the genome 6 . However, thus far only about 700 unique microRNAs have been identified in humans 7 . Traditional methods for discovering microRNAs have relied on cloning and Sanger sequencing 8, 9 . The vast dynamic range of microRNAs (5 log or higher) can result in the domination of the data by a few highly expressed microRNAs, limiting the identification of less abundant microRNAs. Massively parallel, high-throughput sequencing (deep sequencing)
provides the means to identify the expression of millions of small RNA transcripts in a single tissue type, thereby providing a sensitivity of detection that is several orders of magnitude higher than conventional methods.
Mature B cell differentiation is of interest, not only for its role in adaptive immunity, but also because malignancies derived from B cells are common. B cell malignancies reflect defined stages of normal B cell differentiation and constitute the majority of leukemias and lymphomas.
Therefore, we carefully chose a total of 31 samples from normal human B cell subsets and human B cell malignancies to represent the spectrum of normal and malignant B cells (Table 1) .
We reasoned that deep sequencing of a large number of biologically related cases would provide the opportunity to discover new microRNAs, and that shared expression of these microRNAs in separate cases would minimize the rate of false discovery.
In this study, we addressed whether deep sequencing could be used to elucidate the small RNA transcriptome of normal human B cells and human B cell tumors. We analyzed over 328,934,149 separate sequences (6 billion bases) to identify the expression of small non-coding RNAs including microRNA, tRNA, piRNA, snRNA, rRNA and snoRNA. In all, we identified 333
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From mature microRNAs, a number that is over twice as high as previously reported in a single tissue type 17 . We also identified the expression of 286 candidate novel microRNAs, which satisfied the same structural and expression criteria 19 that were used to identify known microRNAs. Through deep sequencing of biological replicates, as well as real-time PCR of known and candidate novel microRNAs, we established deep sequencing as a viable method for reproducibly measuring quantitative microRNA expression. It is anticipated that our work in delineating the expression of small RNAs, including the complete identification of their mature sequences, precursors, genome locations and conservation patterns of microRNAs, will enable a complete exploration of their functional role in normal and malignant B cells. We have thus developed a comprehensive framework that spans the spectrum of identifying new microRNAs using high throughput sequencing and validating them, and then applying real-time PCR in order to provide a clear path to clinical utility.
Materials and Methods

Patient sample processing
Patient samples were obtained using a protocol approved by the Institutional Review Board at Duke University Medical Center and the other collaborating institutions. Total RNA was extracted using the phenol-chloroform method to preserve microRNAs, using Ambion reagents.
Selection of B cell subsets
Tonsils from young patients undergoing routine tonsillectomy were disaggregated and separated by Ficoll. The mononuclear cell layer was harvested, washed in PBS, and resuspended in ACK lysing buffer to remove small numbers of red blood cells. After a wash and resuspension with 10 ml of PBS with 10% Bovine Serum Albumin, cells were counted and 200 million were stained with fluorochrome-tagged monoclonal antibodies to CD19, IgD, CD38 and CD27. The specific monoclonal antibodies employed were anti-CD19-PE-Cy5. , then median centered to 500 and log2-transformed.
MicroRNA Library Preparation and Sequencing
Total RNA (typically 5μg) from each sample was run on denaturing polyacrylamide-urea gels.
The ~17-25 nucleotide RNAs were excised from the gel, ligated to sequencing adaptors on both ends and reverse transcribed. The resulting cDNA library was PCR-amplified for 15 cycles and gel purified on 6% acrylamide gel. The gel-purified amplicon quality and quantity were analyzed on a 6% acrylamide gel relative to oligonucleotides of known concentration and size. 120 μ l of 1-4 pM library were loaded on to the Illumina cluster station, where DNA molecules were attached to high-density universal adaptors in the flow cells and amplified. The DNA clusters generated via this process were sequenced with sequencing-by-synthesis technology, where successive high-resolution images of the four-color fluorescence excitation dependent on the base incorporated during each cycle were captured. Sequencing reads were generated for each of the 31 samples and base calls were rendered using Illumina software. All the primary sequencing data and gene expression data is publicly available through the GEO archive through accession
GSE22898
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Activation of B cells
B cells were selected from peripheral blood of normal individuals using an antibody for CD19 and magnetic beads. These peripheral blood B cells were incubated with CpG and polyclonal antibodies to IgM and CD40 for 24 hours and then harvested.
Transformation of B cells with Epstein-Barr virus (EBV)
Peripheral blood B cells from normal individuals were incubated with high titers of the EBV virus and incubated for 10 days. Those cells that were replicating autonomously were cultured separately for 7 days and RNA was extracted.
Gene Expression Profiling
Gene expression profiling was performed on three replicates of each B cell subpopulation using standard Affymetrix protocols, as described previously 10 . Briefly, 1 μg of total RNA was reversed transcribed using an oligodT primer and cDNA was synthesized. In vitro transcription using a T7 primer was used to generate labeled cRNA, which was fragmented and hybridized to Affymetrix whole-genome U133 plus 2.0 microarrays. The arrays were scanned and data normalized as described previously. The data have been deposited in the publicly available Gene Expression Omnibus database (GSE12366).
Tumor samples from 101 patients with diffuse large B cell lymphoma were obtained at the time of diagnosis and freshly frozen. These cases were profiled using Affymetrix Gene 1.0 ST arrays.
The molecular subgroups were distinguished using a Bayesian approach described previously 10 . significantly over-represented microRNA seed sequences were identified (chi-square test, p<0.001). Genes that were differentially expressed in these binary distinctions for which ontology data for molecular function existed were analyzed using GOEAST program 12 . Gene ontology terms were considered significantly enriched at p <0.001.
GO Term Enrichment analysis
Comparison of RT-PCR and Sequencing Data
Sequencing frequency for each microRNA was scaled to the total number of known microRNA sequences identified in the sample. These scaled frequencies were multiplied by 10 6 and log2-transformed for the purpose of comparison between samples to the normalized RT-PCR data.
Chromatin Immunoprecipitation
Primary germinal center and memory B cells were crosslinked with 1% formaldehyde for 10 minutes at 37 °C and terminated with 0.125 M glycine for 5 min at room temperature. Cells were lysed in hypertonic lysis buffer (5mM Tris-HCl [pH 7.5] (Teknova), 85mM KCl, and 0.5% NP-40) on ice for 10 min. After centrifugation at 6,000 rpm for 5 min at 4 °C, the pellets of nuclei were lysed in ChIP lysis buffer (0.5% SDS, 1% NP-40, 0.5% sodium deoxycholate in 1XPBS)
and sonicated (Ultrasonic CV-18) to shear chromatin DNA to about 500 bp fragments. 1/20 of each nuclear lysate was kept for input and the rest was incubated for 4 hours with Dynabeads ( Invitrogen) that were coupled overnight with either the anti-H3K4me3 antibody (Millipore, 07-473) or the anti-CD20 antibody (Santa Cruz Biotechnology, sc-15361). Precipitated chromatin DNA was eluted with elution buffer (1% SDS, 1% NaHCO 3 ) and purified using the Qiagen MinElute PCR purification kit. The library was subsequently sequenced, and semi-quantitative PCR was carried out using primers to amplify the putative promoter region of the microRNA cluster (-226 to +49 relative to the predicted transcription start site, which is 4439 bp upstream of the first microRNA gene in the novel cluster).
Results
Deep Sequencing Identifies the Small RNA Transcriptome of Normal and Malignant B cells.
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All bioinformatics analyses were performed using a cluster of 1024 Linux computer nodes.
Preprocessing was carried out using locally written Shell and Perl scripts.
From the raw sequences generated by high-throughput sequencing, the 3'-and 5'-adaptor sequences were trimmed. Low quality sequences were identified as those sequencing reads that contained stretches of consecutive identical bases or uncalled nucleotides (N) in the first 12 bases and sequencing reads shorter than 17 nucleotides. To minimize redundancy, reads were initially curtailed to the first 22 nucleotides and identical sequences were represented with a single fasta entry for analysis. Each unique sequence was mapped to the reference genome (Ensembl, build 50) and reads were filtered such that only perfect alignments (full length, 100% identity) were retained. Reads that aligned to more than five positions in the genome and reads that overlapped with the UCSC RNA genes were identified and excluded from microRNA analysis. Additional details regarding our methods are included in the supplement.
Sequencing reads that mapped to known non-coding RNAs other than microRNAs 14 were annotated separately. For each read, flanking sequences were retrieved from the genome and potential secondary structures were predicted using RNAfold 15 . Predictions of miRNA were made using miRDeep 13 which evaluated the sequences that indicated microRNA precursor processing, and the thermodynamic energy of folding these precursors. The predicted probability and the thermodynamic energy of the microRNA precursor structures were consistent with previously described criteria for identifying microRNAs 16 . An example of microRNA sequences that met the criteria for identifying a known microRNA (miR-20b) is shown in Figures 1B-1D . Sequences that occurred 20 or more times in at least one sample were consolidated and annotated for the 31 samples. Genomic loci that overlapped with microRNAs described in miRBase (version 13) were identified as known microRNAs. The remaining genomic loci were identified as encoding candidate novel microRNAs. In order to carefully calibrate the performance of our sequencing and bioinformatic approach, we performed multiplexed real-time PCR for 360 known microRNAs on biologic replicates of the same normal B cell types. We found a high degree of overlap between the detection of microRNAs using both methods. For those 360 microRNAs that we measured using both multiplex real-time PCR and deep sequencing, we found that 64 of the 88 miRNAs were measured using both methods corresponding to a sensitivity of 72%, whereas 230/272 miRNAs were not detected by either method, corresponding to a specificity of 84%. Additional details regarding the calculation of sensitivity and specificity, as well as an alternative method of determining these statistics, which produced similar results, are described in Text S1 and Figure   S1 .
In all, we identified 619 microRNA precursor loci from normal and malignant B cells. The 333 microRNA precursor loci annotated in miRBase 5 were identified as known microRNAs (Supplement Table 2 ), whereas the remaining 286 precursor loci were identified as candidate novel microRNAs (Supplement Table 3 ). Among these known microRNAs, there were 22 mature sequences (Supplement Table 2 ) that mapped to the ostensible microRNA* sequences and were expressed at levels that were comparable or, in some cases, higher than their complementary microRNAs. These previously unknown sequences likely reflect the influence of recently described pathways [17] [18] [19] that allow both the microRNA and the microRNA* strands to independently exert their regulatory functions.
In addition to microRNAs, we identified the expression of other small RNAs, including transfer RNA (tRNA), and ribosomal RNA (rRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), piwi-interacting RNA (piRNA) and a recently described class of small RNAs, tiny RNA 20 (tiRNA) in our data. The expression of these RNAs is shown in Figure 2A (primary data in Supplement Table 4 ).
Deep sequencing reproducibly measures microRNA-expression in biologic replicates.
We compared the expression of microRNAs identified by high-throughput sequencing and our analytic approach. In each of the biologic replicates ( Figure 2B ), we found that the measured microRNA expression in the biologic replicates were highly correlated (P<10 -6 , correlation test
for each comparison), confirming that our approach produces robust results. We further examined the expression of 107 microRNAs that we had previously identified as being differentially expressed among B cell transitions 21 . We compared the expression of these microRNAs as measured by real-time PCR and deep sequencing ( Figures 2C-2E ), and found highly concordant results with over 90% of the differentially expressed microRNAs demonstrating identical patterns of expression regardless of the method of measurement (P<10 -6 , chi-squared test).
Therefore, we concluded that our sequencing and analytic approach reproducibly identified microRNA expression in biologic replicates, and the differential microRNA expression measured by deep sequencing and real-time PCR produced similar results.
Hundreds of known and novel microRNAs are expressed in normal and malignant B cells.
Roughly two-thirds of the microRNAs measured in each cell type were known microRNAs ( Figure 3A ), whereas the rest were candidate novel microRNAs. In general, the expression of candidate novel microRNAs was lower than that of the known microRNAs, although there was considerable overlap between their expression levels. We also found that the correlation of microRNA expression measured by real-time polymerase chain reaction (RT-PCR) and sequencing was similar for both known and candidate novel microRNAs ( Figure S2 ). The number of known and novel microRNAs detected in each sample type did not vary significantly between individual sample types or between normal and malignant cases. We examined the known and novel microRNAs present in the different normal B cell subsets and found that the majority of both known ( Figure 3B ) and novel microRNAs ( Figure 3C ) were shared across the B cell lineage.
The vast majority (96%) of the candidate novel microRNAs were found in more than one sample, with only a small minority of microRNAs were expressed exclusively in a specific B cell subset or malignancy ( Figure 3D ). We further examined the expression of these microRNAs in all publicly available small RNA datasets from mammals. The combined number of publicly available samples (N=20) from 4 separate studies 13, 22, 23 (GEO datasets GSE16579, GSE15190, GSE19473, GPL6583, GSE10829) is considerably smaller than that in our study. Nevertheless,
we confirmed the expression of 197 (71%) of the candidate novel microRNAs in those data ( Figure 3E , Supplement Table 6 ). Many of the microRNAs that we identified in normal and malignant B cells were expressed at ten-fold or higher levels in these non B cell cases. These findings suggest that the microRNAs we have identified are broadly expressed and may have roles in a number of diverse tissue types.
We also examined the conservation of the novel microRNAs across four mammals (chimpanzee, rhesus macaque, mouse and dog). We found that over 80% of the identified microRNAs were conserved with two or more species ( Figure 3F ). Our data suggest that there may be speciesspecific differences in microRNA expression, as has been noted previously 24 . In our data, 75% of novel and 80% of known microRNA had more than 100 predicted target genes with a perfectly conserved match in the 3'UTR of the gene in the following species: human, mouse, rat and dog.
We found that 11 % of novel and 9 % of known miRNA had more than 50 predicted target genes. The remaining microRNA had fewer than 50 predicted target genes (Supplement figure   4) . Analysis of ontology 25 of predicted target genes 11 of both known and candidate novel microRNAs expressed during B cell differentiation strongly implicated transcription factor activity as a regulated function, suggesting a potential role of microRNAs in the regulation of these processes (Supplement Table 5 ).
Real-time PCR Independently Confirms the Expression of 92% of the Novel MicroRNAs
For further validation, we selected 86 candidate novel microRNAs that were detectably measured in at the sequencing data from least one of four diffuse large B cell lymphoma (DLBCL) cases. Using stem-loop reverse transcription 26 for quantitative PCR, we tested the expression of the 86 microRNAs in 101 primary tumors from patients with DLBCL and found that 79 (92%) were detectably measured by real-time PCR ( Figure 3G ) in at least 10% of these cases, suggesting that real-time PCR reproducibly identifies microRNAs that are expressed in lymphomas. We also used real-time PCR to measure the expression of 90 known microRNAs in the same 101 samples and found that over 90% of these were also detected in at least 10% of the cases using real-time PCR. We found that six of the seven RT-PCR constructs that targeted RNA hairpins that had low probability of being a microRNA resulted in no detectable signal. These
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MicroRNAs are Efficacious in the Distinction of Clinically Relevant Groups of Lymphoma
Gene expression profiling of patients with DLBCL has demonstrated that the tumors comprise at least two distinct diseases with different response rates to standard chemotherapy regimens 27 .
MicroRNAs have been shown to be robust biomarkers in malignancies 28 . We hypothesized that microRNAs might be used to make this clinically important distinction for which gene expression profiling remains the gold standard. We performed gene expression profiling on 101 DLBCL cases and further subdivided these cases into the molecular subgroups. We found that 25 microRNAs with the highest t-statistic were equally efficacious as the gene expression profiling in differentiating the two groups of DLBCL with over 95% overlap between the classifications rendered by the two methods, using leave out one cross-validation ( Figure 3H ). Interestingly, 6
of these 25 predictor microRNAs (listed in the Supplement) were candidate novel microRNAs, suggesting a biological and clinical relevance for these candidate novel microRNAs in DLBCL tumors. The complete microRNA expression data are included in Supplement Table 8 .
Deep Sequencing Reveals a New Cluster of 6 Novel MicroRNAs
Although microRNAs appear to be distributed throughout the genome, a number of microRNAs have been found in clusters such as miR-17-92 that are transcribed from a single primary transcript and cleaved into the individual microRNAs by the enzyme DROSHA. The discovery of the miR-17-92 cluster greatly accelerated the identification of the function of those microRNAs in a number of biological systems 3, 4 . We found 2 separate clusters of candidate novel microRNAs on chromosome 9 and chromosome 14 (within the IgH locus) respectively.
The first cluster was previously annotated as a hypothetical gene LOC100130622, and subsequently discarded from Refseq when no associated protein was identified. Our data demonstrate that this cluster, conserved only in primates, encodes 6 separate microRNAs ( Figure   4A ). In order to evaluate whether the microRNAs encoded in these clusters originate from the same primary transcript, we took KMS12 multiple myeloma cells which express these
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From microRNAs and used siRNA to knock-down the expression of the microRNA processing enzyme Drosha. This enzyme acts at the first step of microRNA processing by cleaving microRNA precursors from the primary transcript. We found that decreased Drosha expression was associated with increased accumulation of primary transcripts of both the miR-17-92 cluster as well as the novel miR-2355 cluster. (Figure 4B ). MicroRNAs from this cluster were found to be expressed more highly in normal germinal center (GC) B cells compared to memory cells ( Figure 4C ). We computationally predicted the core promoter region at 4 kb upstream from the primary transcript 29 . We performed chromatin immunoprecipitation for H3K4Me3, the histone marker associated with gene expression. DNA bound to this histone marker was found to be selectively enriched in primary GC cells which express this microRNA cluster highly, but not in primary memory B cells ( Figure 4D ). The microRNAs of this cluster all share the same seed sequence, suggesting that they target the same genes. Among the computationally predicted targets of this microRNA cluster 11 , we identified SMAD2 and SMAD3 which are well known mediators of the TGF-beta signaling pathway. We noted that gene expression both SMAD2 and A number of microRNAs have previously been suggested as being tissue-specific. For instance, miR-223 has been suggested as a myeloid-specific microRNA 33 , whereas miR-9, miR-124, miR-128 have been suggested as brain-specific microRNAs 8 . However, our study found expression of all of these microRNAs in the B cell lineage. Our data indicate that the highly increased sensitivity of deep sequencing will challenge currently held notions regarding tissue-specificity of microRNAs, and suggest that the same microRNAs could play different context and lineagespecific roles in different cell types.
MicroRNA expression has a wide dynamic range from a few transcripts to hundreds of thousands of transcripts per cell. Deep sequencing is especially efficacious for the identification of microRNAs expressed at low abundance in a cell. The number of microRNA transcripts needed to exert their effects in a cell is not known, and it is likely to be context-dependent.
Further, it has been demonstrated that some microRNAs containing the hexanucleotide motif AGUGUU can relocalize to the nucleus to potentially regulate the transcription of target genes 37 .
These findings suggest that a few copies of a microRNA in a cell may be adequate to exert profound down-stream effects. We found the same hexanucleotide motif in 5 microRNAs expressed in B cells. It is also conceivable that some of the low-abundance microRNAs that we have identified in our study may be expressed at higher levels in other development stages or in other cell types. This notion is confirmed by our examination of the novel microRNAs in non B cell data. For instance, a number of the microRNAs that we discovered were also present at 10-fold or higher levels in cell lines derived from breast cancer and cervical cancer, suggesting that the microRNAs that we have discovered in B cells have broad biological significance. 
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Second, the important molecular differences in these subgroups might dictate the use of different therapies in these patients. For instance, the benefit of receiving a proteosome inhibitor, bortezomib, appears to be predominantly limited to those patients who have ABC DLBCL 40 .
However, the current methods can only distinguish GCB from non GCB DLBCL in a limited fashion 41 , and have yielded sometimes conflicting results 42, 43 . Gene expression profiling remains the gold standard for the distinguishing the 2 molecular subgroups; however, this is not routinely performed in clinical laboratories. Our data suggest that microRNAs can render this distinction with equal efficacy. Since microRNAs are stable in tissue processed for routine paraffin sections using standard methods 44 , microRNA-based assays would be much easier to implement in the clinical laboratory.
Emerging data have demonstrated a regulatory role for small RNAs in nearly every cellular system examined thus far. A comprehensive delineation of their role in any cellular system must be preceded by a complete identification of the small RNA transcriptome in that system. The microRNAs that we have identified will likely be included in future commercial microarray platforms that would be widely available. The expression and role of individual microRNAs can also be queried using existing methods as we have demonstrated. Thus, we anticipate that our data, which represents the most in-depth examination of small RNA sequences using secondgeneration methods, will serve as a foundation for the exploration of the role of small RNAs in a number of cellular systems. Table 1. B Expression of microRNAs measured by sequencing across two biological replicates for Naïve, Germinal Center, Memory, and Plasma B Cells. The P-values were computed using a correlation-test against the null hypothesis that the data were not correlated; p<10 -6 in all 4 cases. Ninety percent of the 286 novel microRNAs were found to be conserved across humans and one or more additional species, and over 80% were found to be conserved across humans and two or more additional species. E GSEA enrichment score and distribution of TGF-beta pathway genes along the rank of transcripts differentially expressed in high versus low expressors of the miR-2355 cluster.
Expression of the TGF-beta pathway genes were inversely correlated with expression of the microRNA.
For
